Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Nathalie, Denizon"'
Autor:
Kamel Laribi, Delphine Bolle, Mustafa Alani, Habib Ghnaya, Anne Besançon, Jonathan Farhi, Kayane Mheidly, Nathalie Denizon, Alix Baugier de Materre
Publikováno v:
Cancer Medicine, Vol 8, Iss 5, Pp 2188-2195 (2019)
Abstract We performed a retrospective analysis of 93 myelodysplastic syndromes (MDS) patients with intermediate 2 or high‐risk IPSS score to study the impact of Azacitidine (AZA) relative dose intensity (RDI)
Externí odkaz:
https://doaj.org/article/00dbac4ecb4847fa97a68ed480dd9f46
Autor:
Kamel Laribi, Pierre Lemaire, Anne Besançon, Mohamed Kaabar, Sabine Defasque, Marie Coude, Habib Ghnaya, Maïlys Le Guyader, Nathalie Denizon, Fabienne Pineau-Vincent
Publikováno v:
Annales de biologie clinique. 76:445-450
Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm defined by the presence of at least 5×109 G/L monoclonal B lymphocytes in the peripheral blood. It is the most common type of leukemia in adult patients from Western countries. CLL is character
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a5cf9eed4abeb6357c42c8460ad9b5e
https://doi.org/10.1684/abc.2018.1353
https://doi.org/10.1684/abc.2018.1353
Autor:
Johann Rose, Sabine Defasque, Jonathan Farhi, Anne Besançon-Bergelin, Vincent Cussac, Jérôme Debus, Fabienne Pineau-Vincent, Pierre Lemaire, Habib Ghnaya, Nathalie Denizon, Kamel Laribi, Mustafa Alani
Publikováno v:
Annales de biologie clinique. 76:451-457
We report here a case of lymphoplasmacytic lymphoma with IgA paraproteinemia and a case of concomitant Waldenström macroglobulinemia and monoclonal gammapathy of unknown significance. These rare cases show that the isotype of a monoclonal immunoglob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b24b504011ccef7739e349e4b6a9ec34
https://doi.org/10.1684/abc.2018.1357
https://doi.org/10.1684/abc.2018.1357
Autor:
Jonathan Farhi, Catherine Truong, Pierre Lemaire, Habib Ghnaya, Alix Baugier de Materre, Jeremy Sandrini, Nathalie Denizon, Kamel Laribi, Anne Besançon
Publikováno v:
Biology of Blood and Marrow Transplantation. 22:1357-1367
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with an aggressive clinical course. It is grouped with acute myeloid leukemia–related precursor neoplasms in the 2008 World Health Organization classification.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c7836555dbe80773ace420da7d9dcf4
https://doi.org/10.1016/j.bbmt.2016.03.022
https://doi.org/10.1016/j.bbmt.2016.03.022
Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA
Autor:
Alix Baugier de Materre, Anne Besançon, Catherine Truong, Kamel Laribi, Fabienne Pineau-Vincent, Delphine Bolle, Andrea Sandu, Habib Ghnaya, Nathalie Denizon
Publikováno v:
Annals of Hematology. 95:765-769
We evaluated the efficacy and safety of rituximab for the treatment of 23 elderly patients (median age 78 years) with warm autoimmune haemolytic anaemia (AIHA). The median follow-up was 31 months. Patients had received one to five previous treatments
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ec8144f6279524b7415c831f752d28f
https://doi.org/10.1007/s00277-016-2605-2
https://doi.org/10.1007/s00277-016-2605-2
Autor:
Kamel Laribi, Nathalie Denizon, Jonathan Farhi, Anne Besançon, Alix Baugier de Materre, Mustapha Alani, Habib Ghnaya
Publikováno v:
Leukemialymphoma. 59(11)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a29548e31d41673c255b998b627f7b08
https://pubmed.ncbi.nlm.nih.gov/29561205
https://pubmed.ncbi.nlm.nih.gov/29561205
Autor:
Kamel Laribi, Alix Baugier de Materre, Saga Le Bourdelles, Habib Ghnaya, Delphine Bolle, Jonathan Farhi, Anne Besançon, Nathalie Denizon, Mustapha Alani
Publikováno v:
Experimental hematology. 65
Iron overload has been associated with poor overall survival in patients with higher-risk myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation, but has not been investigated in higher-risk MDS patients treated with hypom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0ed5aa078fd2000256b025f6cb16e31
https://pubmed.ncbi.nlm.nih.gov/29883686
https://pubmed.ncbi.nlm.nih.gov/29883686
Autor:
Anne Besançon, Margot Laly, Christelle Jadeau, Habib Ghnaya, Kamel Laribi, Charles Mellerio, Alix Baugier, Nathalie Denizon
Publikováno v:
Clinical Case Reports
Key Clinical Message A patient with multiple myeloma with a mass in the nasopharyngeal was diagnosed. He received melphalan autograft and radiotherapy, and obtained complete remission. He relapsed 3 months later, with meningeal involvement and withou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3258d780512529cc3676667c8002626
https://doi.org/10.1002/ccr3.160
https://doi.org/10.1002/ccr3.160
Autor:
Alix Baugier de Materre, Delphine Bolle, Adrien Tempescul, Anne Besançon, Stéphanie Poulain, Catherine Truong, Kamel Laribi, Jonathan Farhi, Pierre Lemaire, Jean Christophe Ianotto, Andreea Anghel, Habib Ghnaya, Nathalie Denizon
Publikováno v:
Hematological Oncology
Hematological Oncology, Wiley, 2016, ⟨10.1002/hon.2334⟩
Hematological Oncology, Wiley, 2016, ⟨10.1002/hon.2334⟩
International audience; Primary nodal marginal zone lymphoma (NMZL) is a rare disease. There is no current consensus on how to treat it. The bendamustine plus rituximab (BR) regimen is effective for the treatment of follicular and other indolent lymp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b281dea19514150856445ebe22054ea
Autor:
Kamel, Laribi, Adrien, Tempescul, Habib, Ghnaya, Nathalie, Denizon, Anne, Besançon, Andreea, Anghel, Jonathan, Farhi, Catherine, Truong, Pierre, Lemaire, Stephanie, Poulain, Delphine, Bolle, Jean Christophe, Ianotto, Alix, Baugier de Materre
Publikováno v:
Hematological oncology. 35(4)
Primary nodal marginal zone lymphoma (NMZL) is a rare disease. There is no current consensus on how to treat it. The bendamustine plus rituximab (BR) regimen is effective for the treatment of follicular and other indolent lymphomas, but its efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3468ac09cc6ae0c09f72ede63737e1b0
https://pubmed.ncbi.nlm.nih.gov/27443419
https://pubmed.ncbi.nlm.nih.gov/27443419